m6A-related lncRNAs predict prognosis and indicate cell cycle in gastric cancer

Background: N6-methyladenosine (m6A) modification is a common epigenetic methylation modification of RNA, which plays an important role in gastric carcinogenesis and progression by regulating long non-coding RNA (lncRNA). This study is aimed to investigate the potential prognostic signatures of m6A -related lncRNAs in STAD. Methods: The m6A-related lncRNAs with the most significant impact on gastric cancer prognosis in the TCGA database were identified by bioinformatics and machine learning methods. The m6A-related lncRNA prognostic model (m6A-LPS) and nomogram was constructed by Cox regression analysis with the minimum absolute contraction and selection operator (LASSO) algorithm. The functional enrichment analysis of m6A-related lncRNAs was also investigated. The miRTarBase, miRDB and TargetScan databases were utilized to establish a prognosis-related network of competing endogenous RNA (ceRNA) by bioinformatics methods. The correlation of AL391152.1 expressions and cell cycle were experimentally testified by qRT-PCR and flow cytometry. Results: In total, 697 lncRNAs that were identified as m6A-related lncRNAs in GC samples. The survival analysis showed that 18 lncRNAs demonstrated prognostic values. A risk model with 11 lncRNAs was established by Lasso Cox regression, and can predict the prognosis of GC patients. Cox regression analysis and ROC curve indicated that this lncRNA prediction model was an independent risk factor for survival rates. Functional enrichment analysis and ceRNA network revealed that the nomogram was notably associated with cell cycle. qRT-PCR and flow cytometry revealed that downregulation of GC m6A-related lncRNA AL391152.1 could decrease cyclins expression in SGC7901 cells. Conclusion: A m6A-related lncRNAs prognostic model was established in this study, which can be applied to predict prognosis and cell cycle in gastric cancer.

[1]  Rosa A. Uribe,et al.  CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming , 2021, Advanced science.

[2]  Yuping Wang,et al.  MicroRNA profiles in five pairs of early gastric cancer tissues and adjacent non-cancerous tissues , 2021, Oncology letters.

[3]  M. Kanda,et al.  Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer. , 2021, Histology and histopathology.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  W. Gong,et al.  Genetic variants in m6A regulators are associated with gastric cancer risk , 2021, Archives of Toxicology.

[6]  Se-Jae Kim,et al.  Effects of p-coumaric acid on microRNA expression profiles in SNU-16 human gastric cancer cells , 2020, Genes & Genomics.

[7]  Rui Zhang,et al.  Dynamic landscape and evolution of m6A methylation in human , 2020, Nucleic acids research.

[8]  C. Du,et al.  Integrative analysis of immune microenvironment-related CeRNA regulatory axis in gastric cancer. , 2020, Mathematical biosciences and engineering : MBE.

[9]  B. Zhang,et al.  m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer , 2020, Molecular Cancer.

[10]  Yun Wang,et al.  METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway , 2020, Frontiers in Oncology.

[11]  Zhi-Yong Yang,et al.  Integrated analysis and knockdown of RAB23 indicate the role of RAB23 in gastric adenocarcinoma. , 2019, Annals of translational medicine.

[12]  Yunshu Su,et al.  m6A RNA Methylation Regulators Contribute to Malignant Progression and Have Clinical Prognostic Impact in Gastric Cancer , 2019, Front. Oncol..

[13]  Zi-Zhen Zhang,et al.  METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer , 2019, Molecular Cancer.

[14]  Q. Ding,et al.  METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance , 2019, Gut.

[15]  Wei Wu,et al.  MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62. , 2019, Biochemical and biophysical research communications.

[16]  Zhenzhen Wang,et al.  MicroRNA-1297 inhibits proliferation and promotes apoptosis in gastric cancer cells by downregulating CDC6 expression. , 2019, Anti-cancer drugs.

[17]  Wen-An Wang,et al.  Long non-coding RNA CASC19 is associated with the progression and prognosis of advanced gastric cancer , 2019, Aging.

[18]  Shuai Guo,et al.  ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1 , 2019, Journal of Physiology and Biochemistry.

[19]  Hongchuan Jin,et al.  Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer , 2019, Cell Death & Disease.

[20]  D. Tang,et al.  The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization. , 2019, Carcinogenesis.

[21]  Yuan Zhou,et al.  miR-188-5p Suppresses Gastric Cancer Cell Proliferation and Invasion via Targeting ZFP91. , 2018, Oncology research.

[22]  Hongye Zhu,et al.  Downregulation of MiR-1297 predicts poor prognosis and enhances gastric cancer cell growth by targeting CREB1. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  Hongchuan Jin,et al.  N6-methyladenosine links RNA metabolism to cancer progression , 2018, Cell Death & Disease.

[24]  Chuan He,et al.  Post-transcriptional gene regulation by mRNA modifications , 2016, Nature Reviews Molecular Cell Biology.

[25]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .

[26]  A. Bayoumi,et al.  Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease , 2016, International journal of molecular sciences.

[27]  Fengqin Wang,et al.  Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis , 2016, International journal of molecular sciences.

[28]  Christopher E. Mason,et al.  Single-nucleotide resolution mapping of m6A and m6Am throughout the transcriptome , 2015, Nature Methods.

[29]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[30]  K. Mimori,et al.  Gene expression of bone morphogenic protein 8B in the primary site, peripheral blood and bone marrow of patients with gastric cancer , 2013, Oncology letters.

[31]  Y. Pommier,et al.  The CDK Subunit CKS2 Counteracts CKS1 to Control Cyclin A/CDK2 Activity in Maintaining Replicative Fidelity and Neurodevelopment , 2012, Developmental cell.

[32]  O. Elemento,et al.  Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons , 2012, Cell.

[33]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[34]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[35]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[36]  R. Jenkins,et al.  Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. , 1999, Genomics.